2-溴-4,6-二甲基吡啶 | 4926-26-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-4,6-二甲基吡啶
• 中文别名: 2-溴-4-二甲基吡啶
• 英文名称: 2-bromo-4,6-dimethyl pyridine
• 英文别名: 2-bromo-4,6-lutidine；2-Brom-4,6-dimethyl-pyridin；2-Bromo-4,6-dimethylpyridine
• CAS: 4926-26-5
• 化学式: C₇H₈BrN
• 分子量: 186.051
• InChiKey: IRTOCXBLUOPRFT-UHFFFAOYSA-N

物化性质

• 沸点：
  68°C/0.8mmHg(lit.)
• 密度：
  1.415±0.06 g/cm3(Predicted)
• 最大波长(λmax)：
  268nm(EtOH)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-4,6-dimethylpyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-4,6-dimethylpyridine
CAS number: 4926-26-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8BrN
Molecular weight: 186.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-4,6-二甲基吡啶 在 potassium permanganate 、 四(三苯基膦)钯 、 硼烷四氢呋喃络合物 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 水 、 甲苯 、 叔丁醇 为溶剂， 生成 (6-phenylpyridine-2,4-diyl)dimethanol
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Phenylenebis(methylene)- Linked Bis-tetraazamacrocycles That Inhibit Human Immunodeficiency Virus Replication. 2. Effect of Heteroaromatic Linkers on the Activity of Bicyclams

  摘要：

  A series of bicyclam analogs connected through a heteroaromatic linker have been synthesized and evaluated for their inhibitory effects on HIV-1 (IIIB) and HIV-2 (ROD) replication in MT-4 cells. The activity of pyridine- and pyrazine-linked bicyclams was found to be highly dependent upon the substitution of the heteroaromatic linker connecting the cyclam rings. For example, 2,6- and 3,5-pyridine-linked bicyclams were potent inhibitors of HIV-1 and HIV-2 replication, whereas the 2,5- and 2,4-substituted pyridine-linked compounds exhibited substantially reduced activity and, in addition, were found to be highly toxic to MT-4 cells. We have subsequently discovered that these effects are not unique; amino-substituted linkers also have the potential to deactivate phenylenebis(methylene)-linked bicyclams. A model is proposed to explain the deactivating effects of the pyridine group in certain substitution patterns based on the ability of the pyridine nitrogen to participate in pendant conformations (complexation) with the adjacent azamacrocyclic ring, which may involve hydrogen bonding or coordination to a transition metal. The introduction of a sterically hindering group such as phenyl at the 6-position of the 2,4-substituted pyridine-linked bicyclam appears to prevent pendant conformations, providing an analog with comparable anti-HIV-1 and anti-HIV-2 activities to the parent m-phenylenebis(methylene)-linked bicyclam, The results of this study have been used to develop a quantitative structure-activity relationship model with improved predictive capability in order to aid the design of antiviral bis-azamacrocyclic analogs.

  DOI：

  10.1021/jm950584t
• 作为产物：
  描述：

  2-氨基-4,6-二甲基吡啶 在 氢溴酸 、 溴 、 sodium nitrite 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 0.5h， 以68%的产率得到2-溴-4,6-二甲基吡啶
  参考文献：
  名称：

  天然产物 CCR5 拮抗剂 Anibamine 及其三种烯烃异构体的区域和立体选择性合成

  摘要：

  天然产物anibamine及其三种烯烃异构体的合成已经通过高度区域和立体选择性反应简洁有效地实现。关键步骤包括通过 Sonogashira 偶联和立体选择性 Suzuki 偶联进行的区域选择性钯催化炔基化。进行了进一步的构象分析和体外钙动员研究以表征化合物的生物学特性。

  DOI：

  10.1021/jo2013669

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• 含吡啶结构的化合物、制备方法及其用途
  申请人：佛山市赛维斯医药科技有限公司

  公开号：CN108047215A

  公开（公告）日：2018-05-18

  本发明涉及医药技术领域，具体而言，本发明涉及一类含吡啶结构的化合物、其制备方法、及在制备治疗呼吸系统疾病等中的应用。其中，R1和R2独立选自H、C1‑C10的烷基、C3‑C8的环烷基；R3选自C1‑C10的烷基、C3‑C8的环烷基。
• Heterocyclic Compound
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20180155333A1

  公开（公告）日：2018-06-07

  The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有促醒素受体拮抗活性的化合物，预计可用作药物，如预防或治疗睡眠障碍、抑郁症、焦虑症、恐慌症、精神分裂症、药物依赖、阿尔茨海默病等的药剂。 本发明涉及由以下式（I）表示的化合物： 其中每个符号如规范中定义，或其盐。
• [EN] PYRROLE COMPOUNDS<br/>[FR] COMPOSÉS PYRROLE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010024451A1

  公开（公告）日：2010-03-04

  The present invention relates to a compound represented by the formula: wherein A is pyridyl group having at least one substituent wherein R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, R4 and R6 are each a hydrogen atom, a halogen atom or a C1-6 alkyl group optionally substituted by halogen, R5 is a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, and R7 is a hydrogen atom or a C1-6 alkyl group optionally substituted by halogen or a salt thereof, or a pharmaceutical composition containing the same.

  本发明涉及一种由下式表示的化合物：其中A是吡啶基团，具有至少一个取代基，其中R1、R2和R3各自是氢原子、卤素原子、可选地由卤素取代的C1-6烷基团或可选地由卤素取代的C1-6烷氧基团，R4和R6各自是氢原子、卤素原子或可选地由卤素取代的C1-6烷基团，R5是氢原子、卤素原子、可选地由卤素取代的C1-6烷基团或可选地由卤素取代的C1-6烷氧基团，R7是氢原子或可选地由卤素取代的C1-6烷基团或其盐，或包含该化合物的药物组合物。
• Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors
  作者：Roberta Tesch、Marcel Rak、Monika Raab、Lena M. Berger、Thales Kronenberger、Andreas C. Joerger、Benedict-Tilman Berger、Ismahan Abdi、Thomas Hanke、Antti Poso、Klaus Strebhardt、Mourad Sanhaji、Stefan Knapp

  DOI：10.1021/acs.jmedchem.0c02144

  日期：2021.6.24

  cancers. Chemical tools to clarify the roles of SIK in different diseases are, however, sparse and are generally characterized by poor kinome-wide selectivity. Here, we have adapted the pyrido[2,3-d]pyrimidin-7-one-based p21-activated kinase (PAK) inhibitor G-5555 for the targeting of SIK, by exploiting differences in the back-pocket region of these kinases. Optimization was supported by high-resolution

  盐诱导激酶 (SIK) 是关键的代谢调节因子。 SIK 功能失衡与多种癌症的发生有关，包括乳腺癌、胃癌和卵巢癌。然而，阐明 SIK 在不同疾病中的作用的化学工具很少，并且通常具有较差的激酶组选择性。在这里，我们通过利用这些激酶后袋区域的差异，对基于吡啶并[2,3- d ]嘧啶-7-one的p21激活激酶（PAK）抑制剂G-5555进行了改造，用于靶向SIK 。优化得到了 G-5555 与已知脱靶 MST3 和 MST4 结合的高分辨率晶体结构的支持，从而产生了化学探针 MRIA9，该探针具有双重 SIK/PAK 活性以及优于其他激酶的选择性。此外，我们发现 MRIA9 使卵巢癌细胞对有丝分裂剂紫杉醇治疗敏感，证实了基因敲低研究的早期数据，并建议使用 SIK 抑制剂和紫杉醇联合治疗治疗紫杉醇耐药的卵巢癌。